GFAP and Alzheimer disease: In our study, after GLENVs treatment, the 5×FAD mice reported a significant decrease in the number of Aβ plaques, the Aβ area, and the expression of IBA1 and GFAP, accompanied by a significant reduction in inflammatory factors, suggesting that the administration of GLENVs may attenuate the Aβ pathology and neuroinflammation in AD mice.